Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Lexicon Pharmaceuticals, Inc.
Type
Public
Traded as NASDAQ: LXRX
Industry Pharmaceutical
Founded The Woodlands, TX, 1995
Headquarters The Woodlands, United States
Key people
Lonnel Coats, President and Chief Executive Officer
Brian P. Zambrowicz, EVP & Chief Scientific Officer
Jeffrey L. Wade, EVP of Corporate Development & Chief Scientific Officer
Alan J. Main, EVP of Pharmaceutical Research
Pablo Lapuerta, EVP of Clinical Development & Chief Medical Officer
James F. Tessmer, VP of Finance and Accounting
Number of employees
225 (2011)
Website www.lexpharma.com

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering and developing breakthrough treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Arthur T Sands, Ray B Webb and. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.

The company's clinical drug candidates include sotagliflozin (LX4211) for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl (LX1032) for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis.

Lexicon Pharmaceuticals was founded in September 1995 as a biotech venture of Baylor College of Medicine. The company went public in April 2000 with one of the largest initial public offerings in biotech history ($220 million). In June, 2001 Lexicon purchased a privately owned small chemical library synthesis company, Coelacanth Corporation in Princeton, New Jersey, which became the site for the company's small molecule and medicinal chemistry efforts. The company's original name was Lexicon Genetics Incorporated, but in 2007, the name changed to Lexicon Pharmaceuticals, Inc. to reflect a renewed focus on drug development.

The company initially focused on using gene knockout technology to define the function of genes. This effort complemented and benefited from the international effort to sequence the human and mouse genomes (see Human Genome Project). Using its proprietary gene trapping and gene targeting technologies, the company created the world’s largest repository of genetically modified mouse embryonic stem cells, known as OmniBank, and established a large-scale mammalian knockout program to discover the physiological and behavioral functions of the most druggable mammalian genes. The information collected from this program is stored in the company’s LexVision database, which contains almost 5,000 gene knockouts studied. Over the years, Lexicon evolved from a genomics company into a drug discovery and development company focused on discovering and developing breakthrough treatments for human disease. The company currently has multiple drug candidates in various stages of clinical trials.

In 2016, the company was ranked #8 on the Deloitte Fast 500 North America list.

Lexicon uses patented gene trapping and gene targeting technologies to generate and study knockout mice to discover the physiological and behavioral effects that result from the disruption of a single gene knockout. Because there is a close similarity in gene function and physiology between mice and humans, with a large majority of human genes having a counterpart in the mouse genome, knockout mouse technology has become a powerful tool in the discovery of new medicines.

The value of Lexicon’s technology in drug discovery has been described in a retrospective analysis by the scientific journal Nature. The conclusion of this analysis was that, in most cases, there was a direct correlation when comparing the physiological characteristics, or phenotypes, of knockout mice to the therapeutic effect of the 100 best-selling drugs of 2001. The tremendous utility of knockout mouse technology was recognized in 2007 with the Nobel Prize in Physiology or Medicine to Drs. Mario Capecchi, Martin Evans, and Oliver Smithies.

In developing small molecule drugs for its validated targets, Lexicon uses sophisticated medicinal chemistry known as "click chemistry." Dr. K. Barry Sharpless, who was awarded the 2001 Nobel Prize in Chemistry, pioneered this set of powerful and reliable tools for the rapid synthesis of novel compounds. Lexicon uses solution-phase chemistry to generate diverse libraries of optically pure compounds that are built using highly robust and scalable organic reactions that allow the company to generate compound collections of great diversity and to specially tailor the compound collections to address various therapeutic target families Lexicon’s medicinal chemists design these libraries by analyzing the chemical structures of drugs that have been proven safe and effective against human disease and using that knowledge in the design of scaffolds and chemical building blocks for the generation of large numbers of new drug-like compounds.

Lexicon operates from two locations found in Texas and New Jersey. The corporate headquarters are in The Woodlands, Texas just north of Houston. This location serves as Lexicon’s primary research facility to discover and validate the company's drug targets and test drug candidates in preclinical research. The company’s clinical development and regulatory team is also based at the corporate headquarters.

Lexicon's campus in Princeton, New Jersey is the home of Lexicon's small molecule medicinal chemistry and preclinical development efforts. This site serves as Lexicon's primary medicinal chemistry site to create new chemical entities for therapeutic development.

Investment goal date:
Dividends reinvested
Lexicon Pharmaceuticals, Inc. LXRX report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-01
--
--
Q4 2017
2018-03-05
--
--
Q4 2017
2018-03-01
--
--
Q3 2017
2017-11-08
-0.2900
-0.2900
Q3 2017
2017-11-06
--
--
Q2 2017
2017-08-01
-0.3300
-0.3300
Q1 2017
2017-05-02
-0.3300
-0.3300
Q4 2016
2017-03-03
-0.3100
-0.3100
Q3 2016
2016-11-01
-0.3500
-0.3500
Q2 2016
2016-08-04
-0.3700
-0.3700
Q1 2016
2016-05-03
-0.3400
-0.3400
Q4 2015
2016-03-01
0.7600
0.7600
Q3 2015
2015-11-06
-0.3400
-0.3400
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BALYASNY ASSET MANAGEMENT LLC
731985
BlackRock Fund Advisors
2977143
BlackRock Inc.
4858490
BlackRock Institutional Trust Company, N.A.
1434807
CLEARBRIDGE, LLC
720030
EAGLE ASSET MANAGEMENT INC
2852309
FMR LLC
15647859
KINGDON CAPITAL MANAGEMENT, L.L.C.
1690273
LOOMIS SAYLES & CO L P
913833
NEA Management Company, LLC
2382286
STATE STREET CORP
1641167
UBS GLOBAL ASSET MANAGEMENT AMERICAS INC
4089419
Ulys, LLC
4321214
Vanguard Group, Inc
4168301
VOYA INVESTMENT MANAGEMENT LLC
719232
Major Shareholders
Name Relationship
Total Shares
Holding stocks
SANDS ARTHUR T
0.2000% (1021329)
LXRX /
Artal International S.C.A.
28.9900% (149253731)
LXRX /
WADE JEFFREY L
0.0100% (48597)
LXRX /
WADE JEFFREY L
0.0100% (50597)
LXRX /
ZAMBROWICZ BRIAN P
0.0500% (278703)
LXRX /
MAIN ALAN J
0.0100% (44230)
LXRX /
BROWN PHILIP M
0.0100% (27306)
LXRX /
Invus Public Equities, L.P.
0.2700% (1369273)
LXRX /
Ulys, LLC
1.0800% (5553292)
LXRX /
Invus, CV
5.8800% (30248505)
LXRX /
% ()